# Role of transient receptor potential channels on pathogenesis and treatment of psoriasis

**Authors:** Ana Merian da Silva, Romina Nassini, Francesco De Logu, Juliano Ferreira

PMC · DOI: 10.1007/s10787-025-02095-0 · Inflammopharmacology · 2026-02-14

## TL;DR

This review explores how TRP channels contribute to psoriasis and how targeting them could lead to better treatments.

## Contribution

The paper provides a comprehensive overview of TRP channels' role in psoriasis pathogenesis and therapy.

## Key findings

- TRP channels like TRPV1, TRPV3, and TRPM8 are involved in psoriasis-related processes.
- TRPV1 desensitization with capsaicin may reduce psoriasis severity and itching.
- TRP channels are potential targets for safer and more effective psoriasis treatments.

## Abstract

Psoriasis is a chronic inflammatory skin disease characterized primarily by hyperproliferation of keratinocytes, infiltration and activation of immune cells, including T lymphocytes and macrophages, as well as increased innervation by sensory neurons. Although several therapeutic options are available, the management of psoriasis remains unsatisfactory, with adverse effects and unmet clinical needs. In this context, channels from the Transient Receptor Potential (TRP) family, which are non-selective cation channels involved in various pathologies, have been identified as potential therapeutic targets for treating psoriasis. Growing evidence suggests the involvement of multiple TRP subtypes in the pathogenesis of psoriasis, including altered expression of vanilloid subtypes, such as TRPV1, TRPV3, TRPV4, TRPV6, the canonical TRPC6, and melastatin TRPM8 in patients. These channels are involved in processes such as keratinocyte differentiation and proliferation, immune cell activation (e.g., T cells), and sensory neuron stimulation. Although there are still few studies on the role of TRPs in the therapies currently used for psoriasis, there is evidence of the activation of TRPV1 and the TRPA1 subtypes in the adverse effects of topical pharmacotherapy and phototherapy. On the other hand, TRPV1 desensitization (usually produced by repeated treatment with the TRPV1 agonist capsaicin) can reduce the severity of psoriasis and pruritus. Thus, the pharmacological modulation of TRP channels represents a promising strategy for developing novel, efficacious, and safer therapies to treat patients with psoriasis. This review aimed to provide a comprehensive overview of the involvement of TRP channels in the pathogenesis and therapeutic approaches to psoriasis.

## Linked entities

- **Proteins:** TRPV1 (transient receptor potential cation channel subfamily V member 1), TRPV3 (transient receptor potential cation channel subfamily V member 3), TRPV4 (transient receptor potential cation channel subfamily V member 4), TRPV6 (transient receptor potential cation channel subfamily V member 6), TRPC6 (transient receptor potential cation channel subfamily C member 6), TRPM8 (transient receptor potential cation channel subfamily M member 8), TRPA1 (transient receptor potential cation channel subfamily A member 1)
- **Chemicals:** capsaicin (PubChem CID 1548943)
- **Diseases:** psoriasis (MONDO:0005083)

## Full-text entities

- **Genes:** TRPA1 (transient receptor potential cation channel subfamily A member 1) [NCBI Gene 8989] {aka ANKTM1, FEPS, FEPS1, p120}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, TRPV3 (transient receptor potential cation channel subfamily V member 3) [NCBI Gene 162514] {aka FNEPPK2, OLMS, OLMS1, VRL3}, TRPM8 (transient receptor potential cation channel subfamily M member 8) [NCBI Gene 79054] {aka LTRPC6, LTrpC-6, TRPP8, trp-p8}, TRPC6 (transient receptor potential cation channel subfamily C member 6) [NCBI Gene 7225] {aka FSGS2, TRP6}, TRPV6 (transient receptor potential cation channel subfamily V member 6) [NCBI Gene 55503] {aka ABP/ZF, CAT1, CATL, ECAC2, HRPTTN, HSA277909}, TRPV4 (transient receptor potential cation channel subfamily V member 4) [NCBI Gene 59341] {aka BCYM3, CMT2C, HMSN2C, OTRPC4, SMAL, SPSMA}
- **Diseases:** Psoriasis (MESH:D011565), skin disease (MESH:D012871), pruritus (MESH:D011537), inflammatory (MESH:D007249)
- **Chemicals:** capsaicin (MESH:D002211)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12995967/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12995967/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12995967/full.md

---
Source: https://tomesphere.com/paper/PMC12995967